HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Eton Pharmaceuticals (NASDAQ:ETON) and raises the price target from $9 to $10.
August 11, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eton Pharmaceuticals' price target has been raised from $9 to $10 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Eton Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100